Madrid, 5 May 2021
The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained, for the second consecutive year, the qualification "EXCELLENT" in the Profarma 2020 Plan, in recognition of its industrial activity and its commitment to development and innovation in our country.
This plan, an initiative of the Ministry of Industry, Energy and Tourism, grants the highest mark to the Spanish multinational, with headquarters in Madrid and a presence in forty countries, as a result of its commitment to the development of the industrial structure in Spain and its investment effort both in production, as in R&D.
Profarma aims to increase the competitiveness of the pharmaceutical industry in Spain and, to this end, each year qualifies the participating companies based on their excellence in different industrial, economic and research aspects.
In 2017 Insud Pharma inaugurated two new injectable drug plants in our country dedicated to the production of sterile products; one in León and another in Guadalajara. Currently, one of these plants participates in filling the vials of one of the vaccines used against Covid-19.
Likewise, last March the European Commission approved the group's first biosimilar, bevacizumab, a treatment for different types of cancer that will be manufactured and will also be produced in Spain.